CSF2 and non-small cell lung carcinoma: Some clinical trials, using GVAX also reported a dose-dependent effect that correlates an enhanced therapeutic benefit using a high dose of injected GM-CSF expressing cells, in patients with melanoma (52), prostate cancer (53), non-small-cell lung carcinoma (54) and other tumors (55).